Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the astra domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/wp-includes/functions.php on line 6114
News
CRISPRBITS Logo

News

Follow the progress CrisprBits is making in its journey!

Announcements

[Click headlines for more details]

Congratulations to Dr. Reety Arora, Senior Scientist and Head of R&D at CrisprBits for being one of the winners of AMR-Quest 2023, conducted by C-CAMP, in their hunt for cutting edge solutions and technology for mitigating antimicrobial resistance. The award will support our proprietary CRISPR-based PathCrisp through its accelerator program, to translate AMR detection at point of care and make these tests market ready.

CrisprBits enters into an exciting strategic partnership with MolBio diagnostics, a global pioneer in point of care testing.

CrisprBits has developed OmiCrisp, a CRISPR- based test to detect SARS-CoV2 and to determine whether it is an Omicron or non-omicron variant.

CrisprBits has raised $250,000 in Pre-seed funding from US-based VJ Group. The funding will be used towards product development, team expansion and for research and development.

Grants

CrisprBits has received a grant from GiveIndia and Crypto Relief for adaptation of OmiCrisp to environmental surveillance.

CrisprBits has been awarded MiniSMART Bio-CPS Grant from the BITS BioCyTiH Foundation for building a frontline deployable detection and screening test for Sickle Cell Anaemia.

Publications

The following manuscript describes our CRISPR based test for the Omicron variant of SARS-CoV-2.
Scroll to Top